A new report has concluded that the Pfizer/BioNTech vaccine is safe and 90.7% effective against symptomatic covid-19 in children aged five to 11 years. Pfizer has already submitted its results to the Food and Drug Administration (FDA).

The trial by US drugmaker Pfizer and German company BioNTech, published Friday by the FDA, looked at 2,268 children of these ages who received two doses of the vaccine three weeks apart. Each dose (10 micrograms) was one-third the amount given to adolescents and adults.

The FDA is expected to vote on the vaccine from Pfizer and BioNTech as early as tomorrow, and if approved, it could be available in the United States by early November.

In anticipation of emergency approval, the United States of America recently announced plans to distribute sufficient doses of the vaccine to all 28 million children between the ages of five and 11 living in its territory.